[go: up one dir, main page]

PE20090312A1 - DERIVADO DE 17 -CIANO-18a-HOMO-19-NOR-ANDROST-4-ENO - Google Patents

DERIVADO DE 17 -CIANO-18a-HOMO-19-NOR-ANDROST-4-ENO

Info

Publication number
PE20090312A1
PE20090312A1 PE2008000992A PE2008000992A PE20090312A1 PE 20090312 A1 PE20090312 A1 PE 20090312A1 PE 2008000992 A PE2008000992 A PE 2008000992A PE 2008000992 A PE2008000992 A PE 2008000992A PE 20090312 A1 PE20090312 A1 PE 20090312A1
Authority
PE
Peru
Prior art keywords
androst
homo
17beta
cyano
alkyl
Prior art date
Application number
PE2008000992A
Other languages
English (en)
Inventor
Joachim Kuhnke
Jan Huebner
Rolf Bohlmann
Thomas Frenzel
Ulrich Klar
Frederik Menges
Sven Ring
Steffen Borden
Hans-Peter Muhn
Katja Prelle
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20090312A1 publication Critical patent/PE20090312A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN DERIVADO DE 17BETA-CIANO-19-NOR-ANDROST-22222-4-ENO DE FORMULA (1), DONDE Z ES O, NOR, NNHSO2R; R ES H O ALQUILO C1-C4; R4 ES H O HALOGENO; R6a ES H; R6b ES H, METILO, HIDROXIMETILENO; R7 ES H, ALQUILO C1-C4, ALQUENILO C2-C3, CICLOPROPILO; R9 Y R10 SON H O SE OMITEN POR LA FORMACION DE UN ENLACE DOBLE ENTRE LOS CARBONOS 9 Y 10; R15 Y R16 SON H O JUNTOS FORMAN METILENO; R17 ES H, ALQUILO C1-C4, ALILO. SON COMPUESTOS PREFERIDOS: 17BETA-CIANO-17ALFA-METIL-15BETA,16BETA-METILEN-18a-HOMO-19-NOR-ANDROST-4-EN-3-ONA, 17BETA-CIANO-15BETA,16BETA-METILEN-18a-HOMO-19-NOR-ANDROST-4-EN-3-ONA, 17BETA-CIANO-6BETA,7BETA;15BETA,16BETA-BISMETILEN-18a-HOMO-19-NOR-ANDROST-4-EN-3-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD GESTAGENA Y SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS MENOPAUSICOS, MENSTRUALES, ENTRE OTROS
PE2008000992A 2007-06-12 2008-06-11 DERIVADO DE 17 -CIANO-18a-HOMO-19-NOR-ANDROST-4-ENO PE20090312A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007027636A DE102007027636A1 (de) 2007-06-12 2007-06-12 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
PE20090312A1 true PE20090312A1 (es) 2009-04-09

Family

ID=38858372

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000992A PE20090312A1 (es) 2007-06-12 2008-06-11 DERIVADO DE 17 -CIANO-18a-HOMO-19-NOR-ANDROST-4-ENO

Country Status (21)

Country Link
US (1) US20090048218A1 (es)
EP (1) EP2178899B1 (es)
JP (1) JP2010529152A (es)
KR (1) KR20100017780A (es)
CN (1) CN101679477A (es)
AR (1) AR066970A1 (es)
AU (1) AU2008261277A1 (es)
BR (1) BRPI0813455A2 (es)
CA (1) CA2689563A1 (es)
CL (1) CL2008001721A1 (es)
DE (1) DE102007027636A1 (es)
ES (1) ES2397879T3 (es)
IL (1) IL202300A0 (es)
MX (1) MX2009013626A (es)
PA (1) PA8784201A1 (es)
PE (1) PE20090312A1 (es)
RU (1) RU2010100334A (es)
TW (1) TW200906846A (es)
UY (1) UY31145A1 (es)
WO (1) WO2008151745A1 (es)
ZA (1) ZA201000185B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
US9676812B2 (en) 2012-12-18 2017-06-13 Washington University Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
RU2700264C2 (ru) 2013-04-17 2019-09-16 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
PT3498725T (pt) 2013-04-17 2021-09-09 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3-dissubstituídos para uso em terapia
PL3021852T3 (pl) 2013-07-19 2021-07-05 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowania
RU2696585C2 (ru) 2013-08-23 2019-08-05 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применение
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
LT3206493T (lt) 2014-10-16 2020-08-25 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
CN118344424A (zh) 2014-10-16 2024-07-16 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
EP3224269B1 (en) 2014-11-27 2020-02-26 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP6745274B2 (ja) 2015-01-26 2020-08-26 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
EP3258939B1 (en) 2015-02-20 2022-09-07 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2992037T3 (es) 2016-07-11 2024-12-05 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización
NZ790226A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C17, C20, and C21 substituted neuroactive steroids and their methods of use
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043833A (en) * 1961-07-14 1962-07-10 Ormonoterapia Richter Spa 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3579509A (en) * 1965-06-21 1971-05-18 Smith Kline French Lab Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids
GB1089945A (en) * 1965-09-23 1967-11-08 British Drug Houses Ltd Steroidal-6-spirocyclopropyl-4-en-3-ones
IL32699A (en) * 1968-07-30 1973-06-29 American Home Prod 6-substituted-13-polycarbonalkyl-18,19 dinorpregn-4-en-3-ones,their preparation and pharmaceutical compositions containing them
FR2081561B1 (es) * 1970-03-03 1973-04-06 Roussel Uclaf
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
FR2139708B1 (es) * 1971-06-01 1974-08-23 Roussel Uclaf
BE795241A (fr) 1972-02-11 1973-08-09 Schering Ag 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation
US3994937A (en) * 1972-02-11 1976-11-30 Schering Aktiengesellschaft 15α,16α-Methylene-4-estren-17β-ols
NL7701384A (nl) * 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
US4252800A (en) * 1979-10-05 1981-02-24 United States Of America 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
EP0785211A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
JP2010529152A (ja) 2010-08-26
CL2008001721A1 (es) 2008-12-19
CA2689563A1 (en) 2008-12-18
EP2178899A1 (de) 2010-04-28
ZA201000185B (en) 2011-03-30
PA8784201A1 (es) 2009-01-23
WO2008151745A1 (de) 2008-12-18
AU2008261277A1 (en) 2008-12-18
ES2397879T3 (es) 2013-03-12
TW200906846A (en) 2009-02-16
UY31145A1 (es) 2009-01-30
KR20100017780A (ko) 2010-02-16
US20090048218A1 (en) 2009-02-19
MX2009013626A (es) 2010-01-20
RU2010100334A (ru) 2011-07-20
AR066970A1 (es) 2009-09-23
BRPI0813455A2 (pt) 2014-12-23
DE102007027636A1 (de) 2008-12-18
EP2178899B1 (de) 2012-10-24
CN101679477A (zh) 2010-03-24
IL202300A0 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
PE20090312A1 (es) DERIVADO DE 17 -CIANO-18a-HOMO-19-NOR-ANDROST-4-ENO
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
PE20080102A1 (es) Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
PE20130590A1 (es) Derivados de tomaimicina como agentes citotoxicos
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
MA29119B1 (fr) Derives de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
DK1513826T3 (da) Hidtil ukendte indolylpiperidinderivater som kraftige antihistamin- og antiallergimidler
PE20080527A1 (es) Derivado de pirimidina como inhibidor de la fosfatidilinositol 3-quinasa (pi3k)
AR051288A1 (es) Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica
ATE517882T1 (de) Chinolinderivate
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20080065A1 (es) Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1
PE20091035A1 (es) Derivados de 2-aminopirimidina
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
BR0313385A (pt) Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
PE20070795A1 (es) Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
PE20090822A1 (es) DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE
DE602005021150D1 (de) 3-substituierte pyridinderivate als h3-antagonisten
PE20090513A1 (es) Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3
DK2201002T3 (da) 5-HT7-receptorantagonister
PE20081495A1 (es) Derivados 4,5-difenilpirrol-2-carboxamida como antagonistas de los receptores cb1
AR072102A1 (es) Derivados de 2-oxo-alquil-1-piperazin-2-ona, su preparacion, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por los receptores p75ntr.
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.

Legal Events

Date Code Title Description
FD Application declared void or lapsed